As a multi-targeted immunomodulator with anti-PD-L1 and B7 (CD80) costimulatory binding to reverse T cell exhaustion [29], it can be extrapolated that atezolizumab offers enhanced lymphopoiesis and count recovery, with mitigation of prolonged lymphopenia from RT. Here, CD274 is linked to lymphopenia.